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Streszczenie
WstŒp: Celem pracy by‡a ocena wartoci ró¿nicowej pierw-
szego oznaczenia stŒ¿enia tyreoglobuliny (Tg) po tyreoidek-
tomii (Tx), a przed ablacj„ kikutów tarczycy u chorych ze
zró¿nicowanym rakiem tarczycy (DTC, differentiated thyroid
carcinoma) jako wskanika obecnoci przerzutów i/lub
ognisk nowotworowych (M).
Materia‡ i metoda: Retrospektywnej analizie poddano dane
517 chorych po Tx z powodu DTC skierowanych w celu
ablacji kikutów tarczycy, obserwowanych nastŒpnie d‡u¿ej
ni¿ 1,5 roku. Z analizy wykluczono pacjentów o niepew-
nym przebiegu choroby i z interferencj„ w badaniu Tg
(a-TgAb[+], odzysk Tg < 80%). Ostatecznie analizowano
wyniki 247 chorych z DTC (1479 lat; 223 kobiet, 24 mŒ¿-
czyzn). Porównano wyniki badaæ TSH, wychwytu 131I nad
szyj„ (Tup24), objŒtoci resztek tarczycy (V) i Tg u chorych
z rozpoznanymi w chwili badania M (Grupa M1; n = 35)
z tymi samymi parametrami u pacjentów bez obserwowane-
go powy¿ej 1,5 roku nawrotu choroby (Grupa M0; n = 212).
Obliczono pole pod krzyw„ ROC stŒ¿eæ Tg w badanej gru-
pie. Wyznaczono wartoæ referencyjn„ stŒ¿enia Tg dla po-
dejrzenia M za pomoc„ krzywej wydajnoci badania Tg.
Wyniki: Grupy M0 i M1 nie ró¿ni‡y siŒ pod wzglŒdem stŒ-
¿enia TSH (mediana 49,7 jm./l vs. 44,3; p = 0,16), objŒtoci
kikutów tarczycy (1,4 vs. 1,1 ml; p = 0,79), ró¿nice dotyczy‡y
natomiast Tup24 (7,6 vs. 3,2%; p = 0,01) oraz Tg (4,5 vs.
96,7 ng/ml; p = 0,000000). Pole pod krzyw„ ROC dla Tg dla
badanej grupy wynosi‡o 0,78 – 0,05 (r. – s.e.m.). Wartoæ
referencyjn„ Tg dla podejrzenia M wyznaczono na 38,1 ng/ml,
czu‡oæ oznaczenia Tg wynosi‡a 0,57 (95%CI 0,390,74),
a swoistoæ 0,96 (95%CI 0,920,98).
Wnioski: Pierwsze stŒ¿enie Tg oznaczone po Tx przybiera
u chorych z przerzutami raka tarczycy wartoci wiŒksze ni¿
u chorych bez tych przerzutów, co wskazuje, i¿ wymienio-
ny parametr mo¿e byæ stosowany jako wczesny wskanik
obecnoci przerzutów raka tarczycy (równie¿ w obecnoci
kikutów tarczycy).
(Endokrynol Pol 2006; 4 (57): 370373)
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Introduction
Measurement of serum thyroglobulin (Tg) concentra-
tion is now a standard follow-up procedure in patients
with differentiated thyroid carcinoma (DTC) after total
thyroid ablation [1, 2]. Its diagnostic value in patients
in whom thyroid remnants are still present is less well
established and few studies have been devoted to the
value of first serum Tg concentration measurement as
an early indicator of incomplete cancer dissection or
metastases in patients who have undergone only thy-
roidectomy before radioiodine treatment [39]. Obvio-
usly, an early indicator of the possible presence of car-
cinoma would be a useful tool in selecting a more or
less aggressive diagnostic and therapeutic approach as
early as the first weeks or months after diagnosis.
The aim of this study was to assess the diagnostic
value of the first Tg level measurement, performed after
thyroidectomy but before other treatment, in patients
with DTC, Tg level to be regarded as an early marker of
either metastases or residual cancer.
Materials and methods
TSH, Tg, anti-Tg antibodies and exogenous Tg recove-
ry (all: DYNOtestfi, BRAHMS, Berlin, Germany) were
determined in 517 patients with DTC submitted for
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Abstract
Introduction: Evaluation of the differential value of the first
thyroglobulin (Tg) concentration, measured after thyroidec-
tomy (Tx) but before thyroid remnant ablation, in patients
with differentiated thyroid carcinoma (DTC) as a marker of
either metastases or residual cancer (M).
Material and methods: Data from 517 patients with DTC
after Tx, with follow-up > 1.5 year were analysed retrospec-
tively. Patients in whom either the course of the disease was
unclear or interference in the Tg test was possible (a-TgAb
[+], Tg recovery < 80%) were excluded from the study. Fi-
nally, the data from 247 patients were evaluated (age: 14
79 years; 223 women, 24 men). The results of TSH, thyroid
radioiodine uptake (Tup24), thyroid remnant volume (V) and
Tg in patients with diagnosed M (group M1; n = 35) were
compared with the same parameters in patients with re-
mission > 1.5 year (group M0; n = 212). The area under the
ROC curve was calculated. The clinical decision limit of Tg
level to be suggestive of metastases was determined by
means of efficiency curve.
Results: Groups M0 and M1 did not differ from each other
with respect to TSH concentration (median 49.7 mIU/l vs
44.3; p = 0.16) or thyroid remnant volume (1.4 vs 1.1 ml;
p = 0.79). However, they did differ with respect to Tup24
(7.6 vs 3.2%; p = 0.01) and Tg (4.5 vs 96.7 ng/ml;
p = 0.000000). Area under ROC for Tg was 0.78 – 0.05 (mean –
– s.e.m.). The decision limit of Tg for suspected M was de-
termined at 38.1 ng/ml, Tg sensitivity was 0.57 (95%CI 0.39
0.74) and specificity 0.96 (95%CI 0.920.98).
Conclusions: First thyroglobulin concentration, determined
after thyroidectomy but before other treatment, is higher
in patients with metastatic DTC than in patients without
such metastases. This indicates that Tg level may be used as
an early marker of either residual or metastatic DTC (even
if thyroid remnants are present).
(Pol J Endocrinol 2006; 4 (57): 370373)
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radioiodine therapy after thyroidectomy and before other
treatment. Patients were excluded from analysis in
whom presence of the disease could not be clearly con-
firmed or excluded at that time and during a follow-up
period of at least 18 months, with anti-Tg antibodies
> 60 U/ml or with recovery of exogenous Tg of less than
80%. Finally, 247 patients (223 women, 24 men, age: 14
79 years) were evaluated, including 177 patients with
papillary carcinoma, 49 with follicular carcinoma and
21 patients with an oxyphilic variant of follicular carci-
noma, at all stages according to the TNM classification.
In all patients who were off L-T4 therapy iodine uptake
in the thyroid bed (Tup24) was measured 24 hours after
oral administration of 4 MBq of 131I. The total volume
(V) of thyroid remnants, well delineated by ultrasound
in 197 patients (AU3 Partner, EsaoteBiomedica, Italy/
/USA, 7.5 MHz probe), was calculated by means of the
following formula: S 0,5 × (an × bn × cn), where a, b, c
are the maximal dimensions of remnant n in the fron-
tal, transverse and sagittal planes. When indicated, ra-
dioiodine therapy was administered and a whole body
scan (WBS) was obtained. All patients were treated and
followed up according to generally accepted recommen-
dations. At least 6 and then 18 months after initial eva-
luation patients were subjected to control examinations
under TSH stimulation. Whole body scanning and neck
ultrasound were carried out and TSH, Tg and Tg reco-
very determined. When indicated, other studies were
performed (chest X-ray, CT, 99mTc-MIBI scintigraphy
and WBS after a large dose of 131I). All patients were
also examined on an ambulatory basis every 6 months.
All data obtained between first thyroid carcinoma
diagnosis and the last available control examination
were evaluated. The results were regarded as abnor-
mal (i.e. indicating either metastases or residual cancer
 group M1) when changes were found, subsequently
diagnosed unequivocally as DTC metastases or as can-
cer residues. When no foci of abnormal radioisotope
uptake were found, no metastases were detected by
other imaging methods (US, X-ray, CT) or when lesions
were found without cytological/histological confirma-
tion of thyroid carcinoma during follow-up of at least
18 months, the patient was classified as free from meta-
stases  group M0.
Thyrotropine concentrations, volumes of thyroid
remnants (V), neck radioiodine uptake (Tup24) and Tg
concentrations were compared between groups M0 and
M1 (the Mann-Whitney U test). In all cases, p = 0.5 was
regarded as the border of statistical significance. Rece-
iver operating characteristic curve (ROC) analysis was
performed to better define the diagnostic value of Tg
concentration. The diagnostic efficiency curve of Tg
determination was plotted and the cut-off was set for
maximum efficiency, as described by Kairisto and Po-
ola [10]. The calculations were performed by the Stati-
stica 5.1 software package (StatSoft, Inc.) and Graph-
ROC for Windows (Turku, Finland).
Results
Metastases were not found in 212 patients (group M0).
At the time of the initial evaluation, metastases were
diagnosed in 35 patients (group M1), including 15 pa-
tients with metastases limited to the lymph nodes,
17 patients with residual cancer or distant metastases and 3
patients with both. Some characteristics of both groups
are presented in Table I.
As demonstrated, statistically significant difference
between groups M0 and M1 was found in the Tg con-
centration. This was higher among patients with diagno-
sed residual cancer/distant metastases than in those with
metastases limited to the cervical lymph nodes (155.0 ng/ml
vs 13.1 ng/ml, p = 0.018; three patients with both types
of metastases were excluded from the analysis).
The areas under the ROC curves for Tg concentra-
tions for the whole group studied, patients with lymph
node metastases and residual cancer/distant metasta-
ses, were 0.78 – 0.05 (median – s.e.m.), 0.66 – 0.09, and
0.83 – 0.08, respectively. The clinical decision limit of
Tg concentration for suspicion of DTC metastases/resi-
dues was identified as 38.1 ng/ml. The sensitivity of Tg
at this level in the group as a whole was 0.57 (95% CI
0.390.74) with a specificity of 0.96 (95% CI 0.920.98).
Discussion
In the early phase of therapy of patients with DTC be-
fore remnant ablation by means of radioiodine, detec-
tion of metastases or local recurrence depends primari-
ly on imaging methods: whole body scans (WBS), neck
Table I
Some characteristics of the groups of patients with and
without metastases/residual cancer detected at the time of
initial evaluation
Tabela I
Niektóre dane uzyskane w momencie pocz„tkowej oceny
charakteryzuj„ce grupy pacjentów z przerzutami/pozosta‡ociami
raka tarczycy i bez nich
Median (range)
Group M0; Group M1; p
n = 212  n = 35
TSH [mIU/l] 49.7 (3.497.4) 44.3 (0.299.7) 0.16
V [ml] 1.4 (0.110.6) 1.1 (0.310.5) 0.79
Tup24 [%] 7.6 (0.241.3) 3.2 (0.328.4) 0.01
Serum Tg [ng/ml] 4.5 (0.1564.0) 96.7 (0.71210.0) 0.000000
373
Endokrynologia Polska/Polish Journal of Endocrinology 2006; 4 (57)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
USG, X-ray and CT. The sensitivity of WBS is, howe-
ver, low in the presence of thyroid remnants and CT
examinations are usually not performed without speci-
fic indications [3]. On the other hand, Tg secreted from
normal thyroid cells is indistinguishable from that pro-
duced by the DTC and, as such, its serum concentra-
tion measurement has been considered inappropriate
for the detection of metastases in the presence of thy-
roid remnants. There are, however, some reports indi-
cating the usefulness of Tg concentration measurement
in the presence of thyroid remnants [3, 6, 8, 9].
We demonstrated that in patients without DTC
metastases serum Tg concentration is lower than in
patients with metastatic carcinoma, especially when
localised to the lungs or the bones. Similar data have
been reported by others [8, 9].
The main source of error related to Tg as an early
index of DTC metastases was its low serum concentra-
tion in some patients with metastatic DTC. It may be
disputed whether this was caused by the insensitivity
of the Tg assay used, by an underestimation of the Tg
concentration as a result of the interference of anti-Tg
antibodies, lack of Tg secretion by thyroid carcinoma
cells or by secretion of conformationally abnormal Tg
molecules not detected by the Tg assay used.
Unfortunately, there is no lower limit for anti-Tg
antibodies below which no interference would be ob-
served in Tg assays. This is certainly a limitation on the
diagnostic value of Tg determination in general but no
reliable method is currently known to detect and/or
overcome this effect. In order to minimise the interfe-
rence, we decided to include in our study only patients
who fulfilled available criteria of Tg assay reliability,
those, that is, with anti-Tg antibodies below the afore-
mentioned cut-off point and with recovery of exoge-
nous Tg of more than 80% [11, 12].
Some reduction in the sensitivity of the tests descri-
bed can be also related to low tumour mass. In our gro-
up of patients small volume lymph node metastases
were characterised by lower Tg levels than the general-
ly larger distant metastases. Similar data are reported
by Lima et al. [6]. Similarly, some less differentiated tu-
mours may produce less Tg, which may result in fur-
ther loss in the sensitivity of its determination [13].
In some patients without subsequently detected
metastases unexpectedly high serum Tg concentrations
were measured. Postsurgical trauma or coexisting thy-
roid inflammation could be considered as being respon-
sible for this effect.
The analysis presented made it possible to determi-
ne the clinical decision limit for serum Tg concentra-
tion above which metastases are likely. In our opinion
certain clinical decisions can justifiably be made in pa-
tients with high serum Tg concentration. A more ag-
gressive diagnostic approach may already be conside-
red during the first visit after the thyroidectomy, such
as a greater dose of 131I administered for thyroid rem-
nant ablation (to obtain greater confidence in their ear-
ly and complete destruction) and possibly an earlier
follow-up visit.
Conclusions
Thyroglobulin concentration determined after thyro-
idectomy but before other treatment in patients with
metastatic DTC is higher than in patients without such
metastases. This indicates that Tg level may be applied
as an early marker of either residual or metastatic DTC.
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